Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qizhijiangtang is a Traditional Chinese Medicine (TCM) formulation developed by Guang'anmen Hospital of the China Academy of Chinese Medicine. It is primarily investigated for the treatment of type 2 diabetes mellitus and its microvascular complications, specifically non-proliferative diabetic retinopathy (NPDR). The formula is designed to address the TCM patterns of deficiency of Qi and Yin combined with blood stasis. Its key components, as indicated by its name, include *Astragalus membranaceus* (Huangqi) and *Hirudo* (Leech/Shuizhi), which are traditionally used to tonify Qi, nourish Yin, and activate blood circulation to resolve stasis. In clinical research, it is evaluated for its ability to regulate glucose metabolism and improve microvascular circulation in diabetic patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qizhijiangtang.